Go ahead, let's see what happens when 100 of us are on you 24/7. Dr. George.
Good post bobby, let's get rid of the bad element here. It might not account for a ton of shares but all in all it is DISINGENUITY and it HAS TO STOP!
Yeah Dr George, yeah right doctor #$%$...lol....you are way too dumb to speak on things like this. Great idea Hopey!
This guy has no ethics nor does he have a life beyond this pitiful board. I pay very kittle attention to this sociopathic liar and I suggest you and others do the same.
Got to admit he's got you with fingers, toes and nose in the cookie jar Dr. Spin. Calling Dr. Spin, please come to the emergency short bashers room. Thank you.lol
Read Hope's Lyin' George thread, I think he just about circles the wagons there. Have a nice day Dr. Spin!
Well then it's about time you started backing up your claims with data instead just posting FUD you want people to accept because you said so...duh
Absolutely, and name calling like "dopey" and all his snarky bs is just a cover and not so becoming of a REAL DOCTOR. What a joke passing himself as a doctor. It seems to me HopeWill has some kind of real training although I am not quite sure of the extent or area of his expertise but I too do appreciate him posting stuff like this that helps in keeping it real here.
You said INOPERABLE.....BIG DIFFERENCE.....now go find where it sais that but I won't be waiting by the computer because IT'S NOT THERE DR.SPIN!
Here's your selection criteria, HELLO?
1.Disease Status. Patients must have a recurrent supratentorial WHO Grade IV malignant glioma based on imaging studies with measurable disease (≥ 1 cm or ≤ 5.5 cm of contrast-enhancing tumor). Prior histopathology consistent with a World Health Organization (WHO) Grade IV malignant glioma confirmed by the study pathologist, Roger McLendon, or his designate.
2.Age. Due to the potential implications of the treatment on the developing CNS, all patients must be ≥ 18 years of age at the time of entry into the study.
3.Prior Therapy. Patients may be included in the study independent of the regimen of previous surgical, radiation, or chemotherapy treatments administered. However, the exclusions listed in the Exclusions below must be followed.
4.Performance Status. The patient must have a Karnofsky Performance Score (KPS) of ≥ 70% at the time of entry.
You see INOPERABLE? DR.SPIN!
Well then Ziopharm's criteria says exactly the same thing so I guess that bodes well for them also. RIGHT? NO IT'S WRONG YOU ARE WRONG IT DOES NOT "IMPLY" THAT AT ALL YOU DR SPIN BUSHKY LIAR.SPIN BACK TO ME TINY DANCER! lol
They gave 220M to XON/ZIOP for two CAR-T targets already. They are also building a facility down the street from Ziopharm. It seems there could be something on the horizon.
All good point hope, the naysayers are close-minded and show lack of integrity. I guess it's because the PPS is rising and the sector is heating again. Keep posting objective material, I love it.
Sentiment: Strong Buy
Gee, you are right there, many out chirping negative trash last night and this morning. All the usual suspects on IV and YMB...Hilarious bunch of pessimists, shorts imo. Market and bios looking better so they are getting desperate as ZIOP is getting a bid again. Say bye bye profit shorties! lol
"Took note that yesterday story out that Novartis is looking to unload its mega large stake in Roche (maybe even w/o a premium), for potential new deals. It might be due to recent update over their potential CAR launch delay, as their T cell program is lacking. They (NVS) also had acquired a young biotech for its IL15 program, just in Phase I, but with no precision control of RheoSwitch, and no total amount for the deal was disclosed (private company) ---- yep, just like w/ J&J last few years ago showed, (& GiLD too), a Pharma might just pay Billions for the right 'advantage' opportunity. If not Novartis or Gilead, or even if not Merck (German) not bright enough, someone will see huge value in I/P advantageous SBT & RTS and vast experience in tx solid tumors w/ ad-RTS-IL12 and future Armored CAR tx with RTS-IL15 and etc, etc...."
Sentiment: Strong Buy
Won't be long now, trend is your friend. Going higher into ASCO.